TiumBio CEO On Successful Partnerships, Ambitions To Develop The Next Afstyla
Multiple Clinical Assets Progressing
TiumBio’s CEO shares his experiences as the original developer of hemophilia therapy Afstyla, the reason the rare disease-specialized company is exploring opportunities in Australia, as well as its R&D plans.
You may also be interested in...
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.
Aside from mixed earnings at major South Korean pharma firms, recent updates across the local industry have included the ongoing leadership dispute at Hanmi Group, the approval and reimbursement of Yuhan’s lazertinib as a first-line NSCLC therapy and the US approval of GC Biopharma’s immuno-globulin product.